Photoredox‐Catalyzed Site‐Selective α‐C(sp
<sup>3</sup>
)−H Alkylation of Primary Amine Derivatives
作者:Melissa A. Ashley、Chiaki Yamauchi、John C. K. Chu、Shinya Otsuka、Hideki Yorimitsu、Tomislav Rovis
DOI:10.1002/anie.201812227
日期:2019.3.18
tertiary amines to oxidatively generate α‐amino radicals is well established, however, primary amines remain challenging because of competitive side reactions. This report describes the site‐selective α‐functionalization of primary amine derivatives through the generation of α‐amino radical intermediates. Employing visible‐light photoredoxcatalysis, primary sulfonamides are coupled with electron‐deficient
Novel compounds of the formula I
1
in which
R, R
1
and R
2
are as defined in Patent claim 1,
are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic illnesses.
The invention relates to novel compounds of formula (I), wherein R, R
1
and R
2
have the meaning as cited claim
1.
According to the invention, the compounds are inhibitors of the coagulation factors Xa and VIIa and can be used for treating thrombosis, myocardial infarct, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis post-angioplasty, intermittent claudication, tumours, tumour related illnesses and/or tumour metastases.
Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia
申请人:——
公开号:US20030187037A1
公开(公告)日:2003-10-02
Novel compounds of the formula I, in which R, R
1
and R
2
are as defined in patent claim 1, are inhibitors of coagulation factor Xa and VIIa and can be employed for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexis, angina pectoris, restenosis after angioplasty, claudicatio intermittens, tumours, tumour diseases and/or tumour metastases.
The present invention is concerned with the preparation of lysosomotropic detergent agents and pharmaceutical composition useful in the treatment of cancer. These compounds are amine derivatives having a pK of 3.5 of the general structure ##STR1## in which R.sub.1 is C.sub.8-30 alkyl, C.sub.8-30 -alkenyl, substituted C.sub.4-30 alkyl or substituted C.sub.4-30 -alkenyl; R.sub.2 is hydrogen or C.sub.1-4 alkyl and Y is an electron withdrawing group, to control the pK, selected from trifluoroethyl, and difluoroethyl.